Allergic conditions are often treated with antihistamines. First-generation antihistamines may interfere with restful sleep, render "morning after" effects, modify learning and memory, and decline work efficiency. On the contrary, second-generation antihistamines, like bilastine, have been shown to decrease allergy symptoms effectively without causing night-time sleep disturbances and adverse events. 

The present study developed a real-world case project to help optimize patient care by recognizing the role of bilastine in allergic conditions where antihistamine treatment is needed. Evidence from the literature, where available, supported these real-world patient cases conducted by the panel members. Any discussion concerning off-label use was considered an expert opinion only. 

The real-world cases presented in this study used bilastine in conditions such as perennial and seasonal allergic rhinitis, chronic urticaria, urticarial vasculitis, and pruritus associated with inflammatory skin conditions. The patients were between 9 and 76 years of age, which rendered information on a full spectrum of patients requiring antihistamines treatment. 

These real-world cases using the second-generation antihistamine bilastine showed favorable outcomes for the treated patients. While effectively relieving symptoms, bilastine was reported to be safe and well-tolerated. 

J Drugs Dermatol. 2020 Feb 1;19(2):145-154. doi: 10.36849/JDD.2020.4835. PMID: 32129958.